Plain-English translation of NCT07059403 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new treatment called designed to help the body fight hepatitis B infection. Researchers are giving healthy adults multiple doses of either the medication or a placebo (a dummy treatment with no active ingredient) to see if it's safe and if it helps the immune system respond correctly.
Hepatitis B is a serious viral infection that can cause long-term liver damage. Currently available treatments work for some patients but not all, so researchers are developing new options like this medication to give patients more choices for managing the disease.
You likely qualify if…
You likely don't qualify if…
You would receive four doses of either the medication or placebo at set intervals. The study includes multiple clinic visits where you'll have blood tests, physical exams, and heart rhythm checks (EKGs) to monitor your safety and see how your immune system responds to the treatment. The entire study lasts about 48 weeks from your first dose, with the most intensive monitoring happening around the time you receive your injections.
AI-generated summary from trial data · Aug 19, 2026 · Not medical advice
Australia
Phase
Safety & dosing
Sponsor
Chimivac INC
Enrollment target
~36 participants
Started
August 2025
Primary completion
April 2027
Age range
18 Years – 55 Years
Sex
Male only
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Clinical Development VP, PhD
Chimivac INC
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.